Found 7 results
Author Title [ Type(Asc)] Year
Filters: Author is Mascola, J  [Clear All Filters]
Journal Article
L. Chang, Dowd, K., Mendoza, F., Saunders, J., Sitar, S., Plummer, S., Yamshchikov, G., Sarwar, U., Hu, Z., Enama, M., Bailer, R., Koup, R., Schwartz, R., Akahata, W., Nabel, G., Mascola, J., Pierson, T., Graham, B., Ledgerwood, J., and Team, T. V. R. C. 311 St, Safety and Tolerability of Chikungunya Virus-Like Particle Vaccine in Healthy Adults: A Phase 1 Dose-Escalation Trial, Lancet, vol. 384, pp. 2046-2052, 2014.
U. Sarwar, Costner, P., Enama, M., Berkowitz, N., Hu, Z., Hendel, C., Sitar, S., Plummer, S., Mulangu, S., Bailer, R., Koup, R., Mascola, J., Nabel, G., Sullivan, N., Graham, B., Ledgerwood, J. E., and Team, T. V. R. C. 206 St, Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial, J Infect Dis, vol. 211, pp. 549-557, 2015.
M. Crank, Gordon, I., Yamshchikov, G., Sitar, S., Hu, Z., Enama, M., Holman, L., Bailer, R., Pearce, M., Koup, R., Mascola, J., Nabel, G., Tumpey, T., Schwartz, R., Graham, B., Ledgerwood, J., and Team, T. V. R. C. 308 St, Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults, PLoS One, vol. 10, p. e0123969, 2015.
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B., Gall, J., King, C., Andrews, C., Sheets, R., Gomez, P., Mascola, J., Nabel, G., Graham, B., and Team, T. Vaccine Re, Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector, J Infect Dis, vol. 194, pp. 1638-1649, 2006.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., and Walker, M., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults, J Infec Dis, vol. 177, pp. 1230-46, 1998.
M. L. Clements-Mann, Weinhold, K., Matthews, T. J., Graham, B. S., Gorse, G. J., Keefer, M. C., McElrath, M. J., Hsieh, R. H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P. F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., Walker, M. C., Stablein, D., Excler, J. L., Tartaglia, J., and Paoletti, E., Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group., J Infect Dis, vol. 177, no. 5, pp. 1230-46, 1998.
J. Ledgerwood, DeZure, A., Stanley, D., Novik, L., Enama, M., Berkowitz, N., Hu, Z., Joshi, G., Ploquin, A., Sitar, S., Gordon, I., Plummer, S., Holman, L., ,, Mascola, J., Koup, R., Sullivan, N., Graham, B., and Team, T. V. R. C. 207 St, Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report, N Engl J Med, 2014.